Amicus Therapeutics (FOLD) Competitors $9.80 +0.07 (+0.72%) (As of 12/20/2024 05:31 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends FOLD vs. EXAS, EXEL, RGEN, MDGL, HALO, IONS, ALKS, LGND, GERN, and MNKDShould you be buying Amicus Therapeutics stock or one of its competitors? The main competitors of Amicus Therapeutics include Exact Sciences (EXAS), Exelixis (EXEL), Repligen (RGEN), Madrigal Pharmaceuticals (MDGL), Halozyme Therapeutics (HALO), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Ligand Pharmaceuticals (LGND), Geron (GERN), and MannKind (MNKD). These companies are all part of the "biotechnology" industry. Amicus Therapeutics vs. Exact Sciences Exelixis Repligen Madrigal Pharmaceuticals Halozyme Therapeutics Ionis Pharmaceuticals Alkermes Ligand Pharmaceuticals Geron MannKind Amicus Therapeutics (NASDAQ:FOLD) and Exact Sciences (NASDAQ:EXAS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, community ranking, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings. Which has better earnings and valuation, FOLD or EXAS? Amicus Therapeutics has higher earnings, but lower revenue than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Amicus Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAmicus Therapeutics$493.67M5.93-$151.58M-$0.34-28.82Exact Sciences$2.69B4.08-$204.15M-$1.17-50.77 Is FOLD or EXAS more profitable? Exact Sciences has a net margin of -7.95% compared to Amicus Therapeutics' net margin of -21.21%. Exact Sciences' return on equity of -6.17% beat Amicus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Amicus Therapeutics-21.21% -15.97% -3.17% Exact Sciences -7.95%-6.17%-2.98% Do analysts rate FOLD or EXAS? Amicus Therapeutics presently has a consensus price target of $16.88, suggesting a potential upside of 72.19%. Exact Sciences has a consensus price target of $72.94, suggesting a potential upside of 22.79%. Given Amicus Therapeutics' higher probable upside, equities analysts plainly believe Amicus Therapeutics is more favorable than Exact Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amicus Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Exact Sciences 0 Sell rating(s) 1 Hold rating(s) 17 Buy rating(s) 0 Strong Buy rating(s) 2.94 Do insiders & institutionals believe in FOLD or EXAS? 88.8% of Exact Sciences shares are held by institutional investors. 2.2% of Amicus Therapeutics shares are held by company insiders. Comparatively, 1.4% of Exact Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more volatility and risk, FOLD or EXAS? Amicus Therapeutics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500. Comparatively, Exact Sciences has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Does the media favor FOLD or EXAS? In the previous week, Amicus Therapeutics had 7 more articles in the media than Exact Sciences. MarketBeat recorded 11 mentions for Amicus Therapeutics and 4 mentions for Exact Sciences. Exact Sciences' average media sentiment score of 0.73 beat Amicus Therapeutics' score of 0.42 indicating that Exact Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amicus Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Exact Sciences 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor FOLD or EXAS? Exact Sciences received 450 more outperform votes than Amicus Therapeutics when rated by MarketBeat users. However, 73.17% of users gave Amicus Therapeutics an outperform vote while only 73.01% of users gave Exact Sciences an outperform vote. CompanyUnderperformOutperformAmicus TherapeuticsOutperform Votes52973.17% Underperform Votes19426.83% Exact SciencesOutperform Votes97973.01% Underperform Votes36226.99% SummaryExact Sciences beats Amicus Therapeutics on 10 of the 18 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Amicus Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for FOLD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FOLD vs. The Competition Export to ExcelMetricAmicus TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.93B$6.57B$5.01B$9.08BDividend YieldN/A3.09%4.87%4.21%P/E Ratio-28.8210.55135.0717.15Price / Sales5.93195.041,120.63116.80Price / CashN/A57.1640.5837.88Price / Book17.825.104.754.78Net Income-$151.58M$151.51M$118.50M$225.60M7 Day Performance4.70%-2.13%-1.85%-1.21%1 Month Performance3.16%-3.13%11.28%3.09%1 Year Performance-25.53%11.54%29.92%16.48% Amicus Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FOLDAmicus Therapeutics4.326 of 5 stars$9.80+0.7%$16.88+72.2%-23.7%$2.93B$493.67M-28.82480Analyst DowngradeEXASExact Sciences4.4854 of 5 stars$60.76-0.8%$72.94+20.0%-11.7%$11.25B$2.50B-52.356,600EXELExelixis4.5077 of 5 stars$36.01+2.8%$31.47-12.6%+43.4%$10.28B$2.08B22.461,310Analyst DowngradeAnalyst RevisionRGENRepligen4.0892 of 5 stars$160.33+2.5%$190.25+18.7%-19.7%$8.98B$639.92M-422.731,783Analyst ForecastPositive NewsMDGLMadrigal Pharmaceuticals4.2369 of 5 stars$310.87+2.1%$347.33+11.7%+39.5%$6.78BN/A-12.1490Positive NewsHALOHalozyme Therapeutics4.9948 of 5 stars$48.39+0.8%$61.11+26.3%+29.1%$6.16B$947.36M15.98390Analyst ForecastPositive NewsIONSIonis Pharmaceuticals4.409 of 5 stars$38.66+5.6%$60.65+56.9%-26.3%$6.10B$803.07M-15.00800Analyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsALKSAlkermes4.6513 of 5 stars$30.76+0.8%$35.42+15.1%+9.3%$4.98B$1.51B15.652,100Positive NewsLGNDLigand Pharmaceuticals4.9816 of 5 stars$123.60+5.7%$147.00+18.9%+65.4%$2.34B$152.42M47.4480Analyst RevisionGERNGeron3.84 of 5 stars$3.79-1.8%$7.15+88.7%+61.6%$2.29B$29.48M-12.06141Short Interest ↓MNKDMannKind3.4926 of 5 stars$6.38-2.4%$8.67+35.8%+105.4%$1.76B$198.96M93.43400Analyst UpgradeAnalyst RevisionNews Coverage Related Companies and Tools Related Companies EXAS Alternatives EXEL Alternatives RGEN Alternatives MDGL Alternatives HALO Alternatives IONS Alternatives ALKS Alternatives LGND Alternatives GERN Alternatives MNKD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:FOLD) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amicus Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amicus Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free FOLD Stock Alerts